Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.8 CHF | -0.92% | +1.41% | +1.89% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 03 | Reliance Insider Sold Shares Worth $1,449,067, According to a Recent SEC Filing | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Electrical Components & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.89% | 333M | - | ||
+4.05% | 44.77B | B+ | ||
+158.51% | 5.01B | B | ||
+5.27% | 3.04B | D | ||
-0.38% | 2.87B | C- | ||
+97.93% | 1.25B | - | ||
-27.93% | 1.16B | D+ | ||
+66.35% | 1.07B | - | ||
-8.64% | 997M | B- | ||
-13.47% | 929M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RSGN Stock
- Ratings R&S Group Holding AG